logo
America's expert on China says fungus smuggling case ‘worse than Covid', urges US govt to ‘sever relations'

America's expert on China says fungus smuggling case ‘worse than Covid', urges US govt to ‘sever relations'

Mint08-06-2025
Days after two Chinese researchers were charged with smuggling a crop-killing fungus into the United States, America's top expert on China warned that if the country is not careful, it could be 'something worse' than COVID-19. He also suggested that the US government should sever relations with China.
Yunqing Jian and Zunyong Liu were charged with conspiracy, smuggling, making false statements and visa fraud for allegedly bringing the fungus Fusarium graminearum into the US, describing it as a potential agricultural terrorism weapon.
The fungus causes Fusarium head blight, usually known as 'scab,' and often infects wheat, barley and other grains on farms during rainy years.
According to the FBI, Liu had small baggies of the fungus stashed in his backpack when he flew to the US last year. After claiming ignorance about the plant material inside them, he said he was planning to use them for research at a University of Michigan lab where Jian worked.
Also Read | Fusarium graminearum: How this crop fungus can impact your health
'Waging war against US': Expert
Commenting on the case, expert Gordon G Chang told Fox News that the couple's actions were akin to waging war against the United States.
Chang, who has lived and worked in China for two decades as Counsel to the American law firm Paul Weiss, warned that unless the US takes strong measures—such as severing ties with China—it could face threats even more severe than Covid.
The origin of the SARS-CoV-2 virus, which sparked the global COVID-19 pandemic, remains highly controversial, with some experts alleging it may have been engineered in a Chinese laboratory.
Calling it an 'attack on the United States,' Chang said, 'Xi Jinping talks about going to war all the time, and he is mobilising all of Chinese society to go to war.'
'So we can lose our country, even though we are the far stronger nation because we are not defending ourselves with the vigour and the determination that is necessary,' he added.
He suggested that the only way to stop this is to sever relations with China.
'I know people think that's drastic, but we are being overwhelmed. We are going to get hit eventually. We are going to get hit really hard, not just with Covid, not just with fentanyl, but perhaps with something worse,' the expert said.
However, agriculture experts interviewed by Reuters said the fungus has been in the US for more than a century, can be prevented by spraying pesticides, and is only dangerous if ingested regularly and in large quantities.
'As a weapon, it would be a pretty ineffective one,' Jessica Rutkoski, a crop sciences professor, wheat breeder and geneticist at the University of Illinois at Urbana-Champaign, told Reuters.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Japan's Takeda weighs India for global trials to speed up drug launches
Japan's Takeda weighs India for global trials to speed up drug launches

Business Standard

timean hour ago

  • Business Standard

Japan's Takeda weighs India for global trials to speed up drug launches

Takeda is also open to partnering with local academia, healthcare providers and technology firms in India for innovation, Das said, without sharing more specifics The plan comes at a time when India's clinical trials market is growing, powered by diverse patient pools, cost efficiency, and a fast-growing hospital network Reuters Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting global clinical trials in India to accelerate the launch of its innovative drugs in the world's most populous nation, its India head told Reuters. The plan comes at a time when India's clinical trials market is growing, powered by diverse patient pools, cost efficiency, and a fast-growing hospital network. Grand View Research expects the market to exceed $2 billion by 2030. "India is a strategic growth market for Takeda, and we are making significant long-term investments... in terms of innovation and building capabilities," said Annapurna Das, the general manager of Takeda's India operations. She did not share financial details of the investments. "We're exploring the opportunity of leveraging India's clinical trial ecosystem," Das said. Takeda is also open to partnering with local academia, healthcare providers and technology firms in India for innovation, Das said, without sharing more specifics. "At this point of time, we are still kind of exploring and evaluating how we want to go ahead," she added. Takeda's eventual aim is to integrate India's research and development "ecosystem" into its global pipeline and expand Indian patients' access to cutting-edge therapies in oncology, neuroscience, gastrointestinal health, and inflammation. The Japanese drugmaker aims to launch key cancer drugs over the next two to three years in India, with a lung cancer drug ready to hit the market this year. There's also a dengue vaccine in its launch pipeline, for which Takeda has tied up with local vaccine maker Biological E., and is awaiting approval from India's drug regulator. Takeda established an innovation centre in Bengaluru, dubbed India's "Silicon Valley", earlier this year to tap the country's tech talent to power its global digital transformation. The centre is expanding to have 750 staff working in AI, data science, engineering, and design, from just over 500 employees currently. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Healthcare IT firm Availity to triple India tech staff by 2026 end
Healthcare IT firm Availity to triple India tech staff by 2026 end

Business Standard

timean hour ago

  • Business Standard

Healthcare IT firm Availity to triple India tech staff by 2026 end

US-based healthcare IT firm Availity will more than triple staff at its India tech centre by end-2026, a senior official told Reuters, as it aims to address cost pressures in the US healthcare system and expand its tech capabilities in India. The company will widen its Bengaluru capability centre, targeting headcount growth to 400 from 250 by end-2025, and to 800 by the end of 2026, Chief Operating Officer Sean Keneally said. Availity, the Novo Holdings-backed healthcare information network, connects payers, insurers, and hospitals. Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk. Availity's India centre currently handles product engineering, infrastructure, and some back-office functions, and will expand into technology, product, operations, and corporate roles, Keneally said. Global capability centers (GCCs) in India, once seen as low-cost outsourcing hubs, now handle operations, finance, research and development for their parent corporations. Availity's India expansion comes amid shifting reimbursement and coverage models in the US healthcare system. The company views the move as timely, as US payers face financial pressure from reimbursement cuts and coverage reductions. Keneally said lower Medicare and Medicaid reimbursement rates have made care "almost unaffordable" for healthcare providers, leaving its customers with limited budgets for innovation. "We're very opportunistic at this point in time, helping them get through the financial troubles that they're going through," he said, adding that customers are seeking technology solutions to address their problems. Keneally said that several of Availity's major customers also operate GCCs in India, and its India centre will collaborate directly with those local teams.

Healthcare IT company Availity to triple India tech staff by end-2026
Healthcare IT company Availity to triple India tech staff by end-2026

Time of India

time2 hours ago

  • Time of India

Healthcare IT company Availity to triple India tech staff by end-2026

Academy Empower your mind, elevate your skills US-based healthcare IT firm Availity will more than triple staff at its India tech centre by end-2026, a senior official told Reuters, as it aims to address cost pressures in the US healthcare system and expand its tech capabilities in company will widen its Bengaluru capability centre, targeting headcount growth to 400 from 250 by end-2025, and to 800 by the end of 2026, chief operating officer Sean Keneally the Novo Holdings-backed healthcare information network, connects payers, insurers, and hospitals. Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk .Availity's India centre currently handles product engineering, infrastructure, and some back-office functions, and will expand into technology, product, operations, and corporate roles, Keneally capability centers (GCCs) in India, once seen as low-cost outsourcing hubs, now handle operations, finance, research and development for their parent India expansion comes amid shifting reimbursement and coverage models in the US healthcare system. The company views the move as timely, as US payers face financial pressure from reimbursement cuts and coverage said lower Medicare and Medicaid reimbursement rates have made care "almost unaffordable" for healthcare providers, leaving its customers with limited budgets for innovation."We're very opportunistic at this point in time, helping them get through the financial troubles that they're going through," he said, adding that customers are seeking technology solutions to address their said that several of Availity's major customers also operate GCCs in India, and its India centre will collaborate directly with those local teams.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store